Dihydropyridines: evaluation of their current and future pharmacological applications

被引：260

作者：

Edraki, Najmeh ^{[1
]}

Mehdipour, Ahmad R. ^{[1
]}

Khoshneviszadeh, Mehdi ^{[1
]}

Miri, Ramin ^{[1
]}

机构：

[1] Shiraz Univ Med Sci, Med & Nat Prod Chem Res Ctr, Shiraz, Iran

来源：

DRUG DISCOVERY TODAY | 2009年 / 14卷 / 21-22期

关键词：

CALCIUM-CHANNEL ANTAGONIST; P-GLYCOPROTEIN INHIBITORS; MULTIDRUG-RESISTANCE; CA2+ CHANNEL; IN-VIVO; 1,4-DIHYDROPYRIDINE DERIVATIVES; GENETIC ALGORITHM; VERTEBRATE CELLS; DELIVERY-SYSTEM; BLOCKERS;

D O I：

10.1016/j.drudis.2009.08.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The 1,4-dihydropyridines (DHPs), a class of drugs, possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel-modulating agents and have experienced widespread use in the treatment of cardiovascular disease. Moreover, it has been demonstrated that DHPs could prove to be highly important as multidrug-resistance-reversing agents in cancer chemotherapy. Recent reports suggest that this class also has other notable activities, particularly as antimycobacterial and anticonvulsant agents. Finally, it might be possible for the DHP motif to serve as a scaffold for other pharmacological applications.

引用

页码：1058 / 1066

页数：9

共 81 条

[61]

Schleifer KJ, 2002, QUANT STRUCT-ACT REL, V21, P239, DOI 10.1002/1521-3838(200208)21:3<239::AID-QSAR239>3.0.CO

[62]

2-W

[63] Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance [J].

Tasaka, S ;

Ohmori, H ;

Gomi, N ;

Iino, M ;

Machida, T ;

Kiue, A ;

Naito, S ;

Kuwano, M .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) :275-277

[64] 1,4-Dihydropyridines as calcium channel ligands and privileged structures [J].

David J. Triggle .

Cellular and Molecular Neurobiology, 2003, 23 (3) :293-303

[65] ENHANCEMENT OF VINCRISTINE-INDUCED AND ADRIAMYCIN-INDUCED CYTO-TOXICITY BY VERAPAMIL IN P388 LEUKEMIA AND ITS SUBLINES RESISTANT TO VINCRISTINE AND ADRIAMYCIN [J].

TSURUO, T ;

IIDA, H ;

YAMASHIRO, M ;

TSUKAGOSHI, S ;

SAKURAI, Y .

BIOCHEMICAL PHARMACOLOGY, 1982, 31 (19) :3138-3140

[66]

TSURUO T, 1983, CANCER RES, V43, P2905

[67] RECEPTOR PHARMACOLOGY OF CALCIUM ENTRY BLOCKING-AGENTS [J].

VAGHY, PL ;

WILLIAMS, JS ;

SCHWARTZ, A .

AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (02) :A9-A17

[68] Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: Selectivity for A(3) receptors [J].

vanRhee, AM ;

Jiang, JL ;

Melman, N ;

Olah, ME ;

Stiles, GL ;

Jacobson, KA .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2980-2989

[69]

Vo D, 1992, Drug Des Discov, V9, P69

[70] Syntheses, calcium channel agonist-antagonist modulation effects, and nitric oxide release studies of [3-(benzenesulfonyl)furoxan-4-yloxy]alkyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-trifluoromethylphenyl, benzofurazan-4-yl, 2-, 3-, or 4-pyridyl)-3-pyridinecarboxylates [J].

Vo, D ;

Nguyen, JT ;

McEwen, CA ;

Shan, RD ;

Knaus, EE .

DRUG DEVELOPMENT RESEARCH, 2002, 56 (01) :1-16

← 1 2 3 4 5 6 7 8 9 →